| Year | Journal | Title | |
|---|---|---|---|
| 2026 | Cellular & Molecular Immunology | DIS3 licenses B cells for plasma cell differentiation in humans |  |
| 2025 | Journal of Experimental & Clinical Cancer Research Journal of Experimental & Clinical Cancer Research | The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in MM, representing a promising therapeutic target to counter relapse | |
| 2025 | Blood | Dual targeting of EZH2 and DOT1L in DLBCL | |
| 2025 | Theranostics | Development of a robust BH3 drug toolkit for precision medicine in hematologic malignancies | |
| 2025 | Theranostics | Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction | |
| 2025 | Hematological Oncology | Synthetic Lethal Combinations of DNA Repair Inhibitors and Genotoxic Agents to Target High‐Risk Diffuse Large B Cell Lymphoma | |
| 2024 | Oxford – The british society of Rheumatology | A case of refractory IgG4-related disease successfully treated with daratumumab and lenalidomide | |
| 2024 | Blood | KDM6A controls immunogenicity in MM | |
| 2024 | Blood Neoplasia | Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma | |
| 2023 | British Journal of Haematology | Anti-PD-1 therapy can possibly reverse CAR T cells exhaustion in DLBCL | |
| 2023 | Frontiers in Oncology | Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma | |
| 2023 | Epigenetics and Chromatin | A novel and user-friendly tool to explore and prioritize variants in whole-exome sequencing data | |
| 2023 | European journal of Haematology | Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3 | |
| 2023 | Clinical Cytometry Wiley | Immunophenotypic portrait of leukemia-associated-phenotype markers in B acute lymphoblastic leukemia | |
| 2023 | Leukemia | EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma | |
| 2023 | Cancer research : Metabolism and Chemical Biology | Var∣Decrypt: a novel and user-friendly tool to explore and prioritize variants in whole-exome sequencing data | |
| 2022 | Internal Journal of Molecular Science | LAIR1, an ITIM-Containing Receptor Involved in Immune Disorders and in Hematological Neoplasms | |
| 2022 | Frontiers in Immunology | The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance | |
| 2022 | Blood | PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma | |
| 2022 | Cancer research : Metabolism and Chemical Biology | Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma | |
| 2022 | Theranostics | Comprehensive Characterization of the Epigenetic Landscape in Multiple Myeloma | |
| 2021 | Cancer research : Metabolism and Chemical Biology | G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor–mediated cell death | |
| 2021 | Cancers | Transcription/Replication Conflicts in Tumorigenesis and Their Potential Role as Novel Therapeutic Targets in MM | |
| 2021 | Clinical Epigenetics | Targeting the Methyltransferase SETD8 Impairs Tumor Cell Survival and Overcomes Drug Resistance Independently of p53 Status in Multiple Myeloma | |
| 2021 | Personalized Medecine | RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma | |
| 2021 | Leukemia | RNA-sequencing Data-Driven Dissection of Human plasma cell Differentiation reveals new potential Transcription Regulators | |
| 2021 | Exploration of Targeted Anti-Tumor Therapy | Multi-omics Tumor Profiling Technologies to develop Precision Medicine in Multiple Myeloma | |
| 2021 | Blood | The Origin of Preplasmablastic Cells | |
| 2020 | Internal Journal of Molecular Science | Role of Polycomb Complexes in Normal and Malignant Plasma Cells | |
| 2020 | Cancers | DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets | |
| 2020 | Haematologica | Kinome expression profiling to target new therapeutic avenues in multiple myeloma | |
| 2019 | Medecine/Sciences | CD38 antibodies in multiple myeloma | |
| 2019 | Leukemia | EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation | |
| 2019 | Cancers | Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells | |
| 2019 | Journal of Clinical Medicine | Phenotype Characterization of Diffuse Large B cell Lymphoma Cells and Prognostic Impact | |
| 2019 | Frontiers in Genetics | Treatment may be harmful : mechanisms/preduction/prevention of drug-induced DNA damage and repair in multiple myeloma | |
| 2019 | Theranostics | Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance | |
| 2018 | Cytometry Part B : Clinical Cytometry | BrdU incorporation in multiparameter flow cytometry : A new cell cycle assessment approach in multiple myeloma | |
| 2018 | Clinical Epigenetics | PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs | |
| 2018 | British Journal of Cancer | DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells | |
| 2017 | ASH | Combined inhibition of two bad prognosis genes: Chk1 and Wee1 as a new therapeutic strategy for Multiple Myeloma [Abstract] | |
| 2017 | ASH | Combined inhibition of two bad prognosis genes: Chk1 and Wee1 as a new therapeutic strategy for Multiple Myeloma [Poster] | |
| 2017 | Oncotarget | CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma | |
| 2017 | Oncotarget | An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy | |
| 2017 | Cytometry Part B : Clinical Cytometry | Automated and Simplified Identification of Normal and Abnormal Plasma Cells in Multiple Myeloma by Flow Cytometry | |
| 2017 | Nucleid Acid Research | Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell | |
| 2017 | Leukemia | RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma | |
| 2017 | Cytometry Part B : Clinical Cytometry | Automated and Simplified Identification of Normal and Abnormal Plasma Cells in Multiple Myeloma by Flow Cytometry | |
| 2017 | Cell cycle | Hypoxia favors the generation of human plasma cells | |
| 2016 | Oncotarget | EZH2 in normal hematopoiesis and hematological malignancies | |
| 2016 | Oncotarget | Differential effects of lenalidomide during plasma cell differentiation | |
| 2016 | Expert Review of Hematology | Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy | |
| 2016 | British Journal of Cancer | Chetomin, targeting HIF-1a/p300 complex, exhibits antitumour activity in multiple myeloma | |
| 2015 | Cell Cycle | Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma | |
| 2015 | PLOS Computational biology | GenomicScape : AnEasy-to-Use Web Tool for Gene Expression Data Analysis. Application to Investigate the Molecular Events in the Differentiation of B Cells into Plasma Cells | |
| 2014 | Oncotarget | Drug metabolism and clearance system in tumor cells of patients with Multiple Myeloma | |
| 2014 | British Journal of Haematology | DNA repair in diffuse large B-cell lymphoma: a molecular portrait | |
| 2013 | Cell cycle | Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma | |
| 2013 | British Journal of Cancer | Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors | |
| 2013 | British Journal of Haematology | DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine | |
| 2012 | Oncotarget | Gene expression-based risk score in diffuse large B-cell lymphoma | |
| 2012 | Oncotarget | Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients | |
| 2012 | Molecular Cancer Therapeutics | Development of gene expression based score to predict sensitivity of multiple myeloma cells to DNA methylation | |
| 2011 | The journal of Immunology | Characterization of a Transitional Preplasmablast Population in the Process of Human B Cell to Plasma Cell Differentiation | |
| 2011 | Haematologica | A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines | |
| 2009 | Blood | An in vitro model of differentiation of memory B cells into plasma blasts and plasma cells including detailed phenotypic and molecular characterization | |
In addition to the publications listed above, our academic partners have filed more than 10 patent applications over the past decade, covering innovative diagnostic and predictive biomarkers of treatment response in hematologic malignancies. Diag2Tec has developed strong expertise in the implementation and application of the associated algorithms.